UK Markets close in 5 hrs 43 mins

Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference
09.09.2021 / 16:41
The issuer is solely responsible for the content of this announcement.

Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference


Halle (Saale) / Munich, Germany, September 9, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced today that Ulrich Dauer, PhD, the Company's Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday September 13, 2021, at 7:00 am ET.
 

A replay of the webcast can be accessed from the Presentations & Webcasts page under News and Events on Vivoryon's website, www.vivoryon.com. The replay will be archived on Vivoryon's website for 30 days after the call.
 

###
 

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.

Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com
 

Media Contact
Trophic Communications

Valeria Fisher / Sophia Hergenhan
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
 

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
 


09.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Vivoryon Therapeutics N.V.

Weinbergweg 22

06120 Halle/Saale

Germany

Phone:

+49 (0)345 555 9900

Fax:

+49 (0)345 555 9901

E-mail:

contact@vivoryon.com

Internet:

www.vivoryon.com

ISIN:

NL00150002Q7

WKN:

A2QJV6

Listed:

Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam

EQS News ID:

1232472


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting